John P. Sharp

2020 - PhaseBio Pharmaceuticals

In 2020, John P. Sharp earned a total compensation of $844.4K as Chief Financial Officer at PhaseBio Pharmaceuticals, a 13% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$120,000
Option Awards$328,000
Salary$386,600
Other$9,819
Total$844,419

Sharp received $386.6K in salary, accounting for 46% of the total pay in 2020.

Sharp also received $120K in non-equity incentive plan, $328K in option awards and $9.8K in other compensation.

Rankings

In 2020, John P. Sharp's compensation ranked 9,283rd out of 13,090 executives tracked by ExecPay. In other words, Sharp earned more than 29.1% of executives.

ClassificationRankingPercentile
All
9,283
out of 13,090
29th
Division
Manufacturing
3,963
out of 5,618
30th
Major group
Chemicals And Allied Products
1,608
out of 2,251
29th
Industry group
Drugs
1,407
out of 1,951
28th
Industry
Pharmaceutical Preparations
1,031
out of 1,456
29th
Source: SEC filing on April 22, 2022.

Sharp's colleagues

We found two more compensation records of executives who worked with John P. Sharp at PhaseBio Pharmaceuticals in 2020.

2020

Jonathan Mow

PhaseBio Pharmaceuticals

Chief Executive Officer

2020

John Lee

PhaseBio Pharmaceuticals

Chief Medical Officer

News

You may also like